LILRB4 and Miyoshi myopathy: LILRB4, SEMA4A, ITGB7, CD70, and CCR1 are particularly promising based on their selective expression, roles in MM pathogenesis, and accessibility for therapeutic targeting (Supplementary Table S1, Table 3).